Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Using a series of more than 1,000 X-ray snapshots of the shapeshifting of enzymes in action, researchers at Stanford ...

Using a series of more than 1,000 X-ray snapshots of the shapeshifting of enzymes in action, researchers at Stanford ...

Unfortunately, there isn't an enzyme for many reactions we would sorely like to catalyze—things like digesting plastics or ...

Given that alcohol is the most frequent functional group found in bioactive natural products and marketed drugs, and is a ...